BiotechTube
Home/Altimmune/Richard Eisenstadt
RE

Richard Eisenstadt

Chief Financial Officer

Altimmune

Therapeutic Areas

ObesityMetabolic Dysfunction-Associated Steatohepatitis (MASH)Hypercholesterolemia

Altimmune Pipeline

DrugIndicationPhase
PemvidutideObesityPhase 2
ALT-400Undisclosed Metabolic IndicationPreclinical

Leadership Team at Altimmune

VK
Vipin K. Garg, Ph.D.
President and Chief Executive Officer
SH
Scott Harris, M.D.
Chief Medical Officer
CM
Cynthia Musante, Ph.D.
Senior Vice President, Research & Development
WS
William Symonds, Pharm.D.
Board Member
JG
John Gill
Board Member
View full Altimmune profile